GLP-1 drugs reshaped employer healthcare costs. Now comes the strategic reset

Over the past year, few developments have had as immediate and measurable an impact on employer-sponsored healthcare costs as the rapid rise of GLP-1 medications.

Originally developed to treat diabetes, these therapies quickly became widely used for weight management. Demand accelerated. Employers responded. And in a short period of time, pharmacy spend projections shifted in ways many organizations had not fully anticipated.

For many employers, decisions had to be made quickly. Coverage policies were expanded in response to employee demand and physician adoption, often without the benefit of long-term utilization data or a fully developed strategy. The result was a significant increase in pharmacy spend that left organizations reassessing both cost and sustainability.

Now, the market is entering a new phase. The introduction and expansion of oral GLP-1 options, including medications like Rybelsus, alongside established injectable treatments such as Wegovy and Ozempic, is changing how these therapies are being positioned and how employers are evaluating them.

The message in the market is clear: these new options may offer a more manageable path forward. Whether that promise holds true will depend less on the drug itself and more on how employers choose to structure access.

This is an important distinction. GLP-1 medications are not a short-term trend. They represent a category that will continue to evolve, expand, and play a role in workforce health benefit strategies. The question for employers is no longer whether to cover these medications. It is how.

That requires a shift from reactive decision-making to intentional strategy.

Employers also need to evaluate GLP-1 medications through a broader lens than pharmacy spend alone. Emerging evidence suggests these therapies may improve long-term cardiovascular and metabolic health outcomes, including reducing the risk of serious cardiac events in certain patient populations. That matters because employers are not only managing prescription costs. They are managing the downstream financial impact of chronic disease, absenteeism, disability, and long-term healthcare utilization.

The conversation, therefore, should not be framed simply as whether GLP-1 medications cost money. The more important question is whether employers are structuring access in a way that improves overall workforce health while managing total cost of care over time.

First, employers must revisit formulary design. Early adoption often meant broad access without clear parameters. Going forward, organizations should evaluate clinical criteria, step therapy protocols, and appropriate use guidelines that align with both health outcomes and cost management.

Second, eligibility and utilization management need to be clearly defined. Not every employee population will require the same level of access, and not every prescription reflects long-term adherence or clinical necessity. Data, not demand alone, should guide these decisions.

Third, employers should take advantage of a more competitive and dynamic marketplace. As additional treatment options emerge, there is greater opportunity to negotiate, structure benefits more effectively, and align coverage with organizational priorities.

Finally, communication matters. Employees are increasingly aware of these medications and their potential benefits. Employers should be transparent about what is covered, why decisions are made, and how those decisions support both individual health and the sustainability of the overall plan.

The rapid rise of GLP-1 medications created real cost pressure because employers were forced to respond in real time to unprecedented demand. What is different now is that there is space to reassess.

This is not simply about cost containment. It is about building a more disciplined, data-driven approach to one of the most significant pharmaceutical shifts in recent years.

GLP-1 medications are here to stay. The opportunity in front of employers is to ensure that the next phase of adoption is more deliberate than the first.

About Patty Starr
Patty Starr is President and CEO of Health Action Council, where she works with employers to design and manage benefits strategies that improve the quality, cost, and value of healthcare.